Does chemotherapy benefit the patient with a central nervous system glioma?
L A Rodriguez, V A Levin
Abstract
L A Rodriguez, V A Levin
Abstract
The authors discuss the results of clinical trials assessing the value of chemotherapy for brain tumors in the adjuvant setting as well as at recurrence. Adjuvant chemotherapy does benefit some patients with malignant brain gliomas. Improved survival rates seem to be related to an increased number of long-term survivors. The most effective chemotherapy is BCNU or a combination of CCNU, procarbazine, and vincristine (PCV). Drugs that potentiate radiation therapy, such as hydroxyurea and BUdR, are also useful in some patients.
OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The authors discuss the results of clinical trials assessing the value of chemotherapy for brain tumors in the adjuvant setting as well as at recurrence. Adjuvant chemotherapy does benefit some patients with malignant brain gliomas. Improved survival rates seem to be related to an increased number of long-term survivors. The most effective chemotherapy is BCNU or a combination of CCNU, procarbazine, and vincristine (PCV). Drugs that potentiate radiation therapy, such as hydroxyurea and BUdR, are also useful in some patients.
Key concepts: Procarbazine, Medicine, Vincristine, Chemotherapy, Lomustine, Oncology, Glioma, Adjuvant